M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 4.18 USD -1.18% Market Closed
Market Cap: 257.1m USD

Intrinsic Value

GLUE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one GLUE stock under the Base Case scenario is 7.69 USD. Compared to the current market price of 4.18 USD, Monte Rosa Therapeutics Inc is Undervalued by 46%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLUE Intrinsic Value
7.69 USD
Undervaluation 46%
Intrinsic Value
Price
M
Base Case Scenario

Valuation History
Monte Rosa Therapeutics Inc

Valuation History Unavailable

Historical valuation for GLUE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Monte Rosa Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Monte Rosa Therapeutics Inc

Current Assets 332.3m
Cash & Short-Term Investments 326.1m
Receivables 1.4m
Other Current Assets 4.8m
Non-Current Assets 60.9m
PP&E 55.6m
Other Non-Current Assets 5.3m
Efficiency

Free Cash Flow Analysis
Monte Rosa Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Monte Rosa Therapeutics Inc

Revenue
159.5m USD
Operating Expenses
-161.6m USD
Operating Income
-2.1m USD
Other Expenses
8.3m USD
Net Income
6.2m USD
Fundamental Scores

GLUE Profitability Score
Profitability Due Diligence

Monte Rosa Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
Negative Revenue Growth Forecast
29/100
Profitability
Score

Monte Rosa Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

GLUE Solvency Score
Solvency Due Diligence

Monte Rosa Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
60/100
Solvency
Score

Monte Rosa Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 16.49 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

Lowest
Price Target
10.1 USD
142% Upside
Average
Price Target
16.49 USD
294% Upside
Highest
Price Target
21 USD
402% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Monte Rosa Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GLUE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

GLUE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one GLUE stock?

The intrinsic value of one GLUE stock under the Base Case scenario is 7.69 USD.

Is GLUE stock undervalued or overvalued?

Compared to the current market price of 4.18 USD, Monte Rosa Therapeutics Inc is Undervalued by 46%.

Back to Top